Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Journal of Thyroid Research · 2014 · 2014 · 1-13
DOI: 10.1155/2014/638747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thyroid Research, 2014. Verfasst von Osamu Tohyama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biomarkers and Personalized Medicine Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan. Die Arbeit wurde bisher 396-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1–4), platelet derived growth factor receptor α (PDGFR α ), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Autor:innen und Institutionen
- Biomarkers and Personalized Medicine Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan.
- Discovery Biology, Oncology Product Creation Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan.
- Biomarkers and Personalized Medicine Core Function Unit, Eisai Inc., 4 Corporate Drive, Andover, MA 01810, USA.
ORCID-Profile: Kiyoshi Okamoto, Yukinori Minoshima
Zitieren
APA
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014). Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. Journal of Thyroid Research, 2014, 1-13. https://doi.org/10.1155/2014/638747
Vancouver
Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. Journal of Thyroid Research. 2014;2014:1-13. doi:10.1155/2014/638747
BibTeX
@article{Tohyama2014,
author = {Tohyama, Osamu and Matsui, Junji and Kodama, Kotaro and Hata-Sugi, Naoko and Kimura, Takayuki and Okamoto, Kiyoshi and Minoshima, Yukinori and Iwata, Masao and Funahashi, Yasuhiro},
title = {Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models},
journal = {Journal of Thyroid Research},
year = {2014},
volume = {2014},
pages = {1--13},
doi = {10.1155/2014/638747}
}
EUVIMED